World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been ...
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback